Arboretum LifeSciences Raises $30 Million in Series A Funding
Arboretum LifeSciences, a company based in Cambridge, Massachusetts, has successfully raised $30 million in its Series A funding round. The company is known for its innovative approach to precision medicine, focusing on smarter diagnostics, efficient clinical trials, and improved care for common diseases.
Investors and Funding Details
The funding round was supported by several prominent investors, including .406 Ventures, Amgen, F-Prime, GV, and Hims and Hers. Unlike typical funding rounds, this one did not have a lead investor.
Company Leadership
Arboretum LifeSciences was co-founded by Anthony Philippakis, who currently serves as the CEO, Clare Bernard as the President, and Craig Lancaster as the Head of Technology. The leadership team is focused on leveraging the new capital to advance their mission in precision medicine.
Use of Funds
While specific plans for the newly acquired funds were not detailed, it is expected that the investment will support the company's ongoing efforts in developing and enhancing their diagnostic tools and trial efficiencies, aimed at better serving patients with common diseases.
Location
The company operates out of Cambridge, Massachusetts, a hub for biotechnology and life sciences innovation.
Arboretum LifeSciences continues to push forward in the field of precision medicine, utilizing the latest funding to enhance their innovative solutions for healthcare.